FemTech Apps Reshaping Pelvic Floor Care

FemTech explained and how pelvic floor care belongs within it

Back in 2016, Ida Tin, who co-founded the Clue period-tracking app, coined FemTech to name tools made specifically for women's health at every age. It now goes beyond periods and pregnancy into care for pelvic and related issues, sex care, and after-birth support, fields long marked by too little funding and quiet pain people avoided saying.

The market-size numbers shift based on who is tracking them. SNS Insider estimates FemTech worldwide as a substantial figure for 2025, reaching roughly four times that amount come 2035. Emergen Research estimates a lower figure for 2025, reaching roughly three times that amount come 2035. Both estimates can be true: one covers more apps and tools, while the other includes more drug and biology work in health. That gap shows this loosely organized industry is still new, not any real disagreement about where it's headed.

According to McKinsey's look at FemTech firms, more than 70% were started by a woman, fitting why so many tools tackle issues that medtech led by men ignored for years. Women account for half of the people these products target, yet FemTech gets only 2% in worldwide funding. The mismatch between those numbers is the real issue here. FemTech shows how a sector might carry a valuation worth tens of billions yet stay starved for the scale of what it tries to fix. America tops FemTech sales according to Emergen Research's figures, and Asia-Pacific is rising quicker than any other region. Pelvic care takes up a tiny part of the whole market, yet the shift from shame to apps shows up most clearly there, since patients had barely any other options.

How pelvic floor apps run: starting with simple logging, moving into guided biofeedback

Those early apps just told people to practice Kegels. No sensor, no readings, nothing showing if a contraction took place or was performed right. Users quit quickly since the app gave no sign the exercise helped, and they abandon something they cannot see when it provides no response.

Sensor-enabled hardware handled it by working alongside an app to track real muscle activity rather than made-up effort. Willow's bought Elvie's business in March 2025, so Willow Innovations now runs Elvie Trainer, which relies on directional force sensing to spot when the user pushes rather than contracting, the most frequent and counterproductive error anyone makes doing Kegels. Finding it during real time, rather than having a user reinforce a bad action, is what matters clinically, though that device sells ease.

Bloom Pod runs on the same idea yet sits within another ecosystem. It’s made from clinical silicone, goes inside the body, tracks pelvic tightening, pressure, and stretch, and is FDA-listed. The unit connects with the Bloom app, pushing biofeedback live to both the user plus her Pelvic Health Specialist. That path beats hardware-only tools: any clinician reviews identical data right then instead of waiting for a follow-up.

Some people can’t buy or don’t want a tool, so app-based plans offer help with exercises without any gear. Above both methods sits an expanding AI layer: systems that study trends in many people's contraction data, set difficulty for each person, and show when they're making progress or when they're regressing. Certain platforms forward the data onward to a specialist in remote pelvic health, making the app a starting point rather than care's endpoint. This spectrum goes from a no-cost app without any sensor toward FDA-listed hardware that passes data along to a clinician; where a tool sits sets what it can fairly say.

What the evidence shows: clinical outcomes, validation gaps, and what "it works" means here

Sword Health's Bloom leads published findings here: 89% reduction of pelvic surgeries versus usual care, plus several times over reduction of pelvic-related doctor visits. A separate review found Bloom's 3.6 to 1 return. Results such as these show why companies and health groups now view treating pelvic floor apps to be something closer to preventive care, not merely a wellness perk.

FDA approval or registration, which the Bloom Pod carries, gives a stronger signal than what a slick landing page puts across, because it shows the device has crossed some minimum bar of clinical proof, something a downloadable app with no hardware and no regulatory filing simply hasn't done. The Bloom Pod carries FDA listing, showing an item has met a minimum bar of clinical evidence, something no downloadable app lacking hardware or regulatory filing simply hasn't done.

The clinical evidence in this category is thinner than the promotional claims make it sound. In Urogynecology, a review published and authored by Zhang, plus Stackpole, with Iglesia from Georgetown University with MedStar Health, said pelvic floor and clinic in-office therapies give people with urinary incontinence real nonsurgical choices, but high-quality, long-term data are scarce, and expenses are high. That review says phone apps help more folks get involved, but they often skip rigorous validation and create real worries regarding privacy and fairness.

Few pelvic floor apps have been tested by outside researchers, and what outcome data there is comes largely from the makers of the product. That pattern is common in the business, but it doesn't equal outside evidence, and seeing it that way is how many people go off track. Confidentiality brings more danger, as pelvic and intimate health information sits among the most personal details someone can share with software, an issue Georgetown/MedStar researchers highlight clearly and one that holds greater significance in a nation where reproductive health access has faced legal changes. Who gets in isn’t spread evenly: price and phone use shape who gains, meaning apps reaching more people still may miss women facing the worst gaps. Even so, the best data still shows real potential. It keeps the upside uneven, packed into options backed by real clinical partnerships, and it puts the work on people and clinicians writing these tools so they can separate an FDA-listed option from a wellness app that just has a pretty surface and zero underneath.

AI's move making pelvic floor apps work as predictive health tools instead of exercise guides

FemTech's overall path is moving from just recording symptoms as they pop up to flagging issues before they fully develop. A World Health Expo's 2026 FemTech report says AI tools are being developed to analyze health data for early insights, which pelvic floor care has been starting to use in limited ways.

Within pelvic floor apps in particular, this looks like finding patterns in contraction data as time goes on, flagging a dip or gain trajectory well before a person picks up on it themselves, and changing a routine to fit how a body responds instead of putting every user through the same exercise plan. This framing has gone from a simple log toward something closer to a guide, one which connects pelvic symptoms with rest, tension, and hormonal rhythm data rather than treating pelvic health like a mechanism that functions apart from the whole self.

Sword Health's setup points to where this is going across the whole platform. The "AI Care" architecture brings together musculoskeletal care and women's health, mind health plus cardiometabolic care in one platform, where Bloom focuses on women's health. The whole sector will probably follow this pattern of platform consolidation once firms see pelvic health is never apart from female physiology.

Software remains FemTech's fastest-growing area, powered by cycle monitoring, telehealth, plus prediction tools using comparable modeling methods. Beyond pelvic health generally, AI-powered imaging built to flag endometriosis sooner highlights just how broad this market's diagnostic goals have grown. Pelvic floor apps are one node in a larger, increasingly connected picture of pelvic health, and what a woman downloads in 2026 is a different category of product than what existed even two years earlier. From here, the gap keeps widening between a simple Kegel alert and an AI-assisted platform that is clinical-grade.

How app-based availability helps women with no other practical choice

Pelvic floor therapists group together in urban areas. Apps aren't. They run wherever a phone picks up coverage, so no patient has to stay close to a city for care, which marks the biggest jump in availability this field has seen.

Price follows the same pattern. Costly in-person procedures or rehab a health plan might not fully cover sit beside a guided app that costs little or nothing. The mid-priced sensor-based trainers fall into an entirely separate cost bracket. When it happens matters as much as price: she can begin one with no referral, no waitlist, and no disclosing details at work, which reduces stigma substantially versus booking a visit through reception.

After having a baby, this gap matters the most: it's a highest-need stretch for fixing pelvic floor problems and, coincidentally enough, when getting to an office is hardest. Bloom targets this mismatch explicitly, fully remote and structured to fit each phase of a mother's journey, delivering specialist-led care for those who couldn't normally access it.

Job-based coverage is now a real way in too. During 2025, Progyny pulled in a substantial sum through fertility help, jumping 14% past the 2024 total, which shows how large employer-sponsored women's health programs grow once firms choose to pay for them. Pelvic floor tools folded into wellness plans at work find women who wouldn't have sought out that care themselves.

Even now, Smartphone-first tools fail to reach women lacking steady data, while apps made in one tongue or ignoring local customs exclude huge groups on purpose. UNICEF's 2025-2030 initiative aims to address gaps in accessibility, which amounts to a concession that the latest run of apps hasn't solved equity. That opening got widened. It still doesn't have a door for all, and mixing those up is where much of the sector's early celebration gets ahead of reality.

What really separates a validated pelvic floor app from a vague one

Regulatory clearance gives the clearest signal, and belongs first on any checklist, not lower after market impressions already exist. An FDA clearance or listing shows a device has passed a baseline evidence bar. Without that mark, a wellness app designation hasn't been earned, period, and the gap ought to guide how much trust people give both options.

What an app actually measures counts as much as the clearance it carries. Devices with sensors confirm how the tissue truly behaves. Instruction-only apps treat it as if the user does the exercise right, a view clinical studies can’t back for many people, since bearing-down is mistaken as the contraction. The oversight someone gets depends on if that app connects with a real clinician. Platforms passing data along to a pelvic health specialist, including remotely, add one layer of oversight that a self-directed app cannot replicate alone.

Company-funded research is just a starting point, even though Published outcome data matters. What truly matters is whether outside, checked research exists, while Georgetown/MedStar's work in the journal Urogynecology shows how that kind of careful assessment should be conducted. Since reproductive health data and pelvic details are so personal, Privacy terms need careful attention too. It matters to see if data is shared with outside firms, how it's kept, and where it goes after a sale, since acquisitions are common here, with Elvie's sale involving Willow Innovations during March 2025 as one point.

These options land at various spots along that range. Willow Innovations now owns Elvie Trainer, which uses directional force sensing to catch bearing-down mistakes as they happen in real time while pairing simple everyday use with true device capability. Bloom Pod, FDA-listed, tracks force, lengthening, and contraction, then sends those numbers to her specialist and the user. Bloom, Sword Health platform overall, is fully remote and specialist-led, part of the AI Care architecture, with published outcome data reporting 89% reduction for pelvic surgeries compared with usual care.

When someone faces prolapse or serious incontinence, a phone app belongs paired with clinical review rather than taking its place. These apps help most by making it easier to begin. The clinician still owns the diagnosis, and no sensor data shifts that split of work.